Vigil Neuroscience (VIGL) News Today

Vigil Neuroscience, Inc. (NASDAQ:VIGL) has seen its shares trade higher amid the announced $470 million acquisition by Sanofi and mixed analyst activity over the past several days. Investors are weighing the strategic value of the Alzheimer’s asset transfer against multiple rating changes and ongoing earnings forecasts.

• Sanofi agreed to acquire Vigil for $8.00 per share upfront plus $2.00 per share in potential milestones, bolstering confidence in Vigil’s TREM2 Alzheimer’s candidate.
• Wall Street consensus price targets imply roughly an 86.7% upside, reflecting optimism around near-term catalyst potential.
• William Blair raised its FY2027 EPS forecast to a loss of $1.78 per share (versus a prior consensus of $2.07), indicating a slight improvement in expected profitability.
• Five analysts maintain an average “Hold” rating on VIGL, with both Markt Perform and Neutral ratings reaffirmed by JMP, William Blair and Wedbush.
• Citizens JMP, William Blair and Wedbush each downgraded VIGL from “Strong Buy” to “Hold,” with Wedbush cutting its price target from $13.00 to $8.00.
• A shareholder alert filed by the Ademi Firm is probing whether the $8.00 takeover price properly reflects shareholder value.